cash flow should be no problem, DNA should have no problem achieving a net profit of $20+ million dollars this financial year.
This stock is a play on the legal outcome, in Singapore and Cambodia.
Singapore arbitration should be ok.
it is the Cambodia legal case that is iffy, from the strong wording in the annual report. I reckon DNA have more than 50% chance of winning the case in the court of appeal.
cash flow should be no problem, DNA should have no problem...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
